BDSX · NASDAQ
Biodesix (BDSX) Stock Price & Fundamentals
Biodesix (BDSX) closed at $452.63 on Oct 9, 2026, down 1.15% from the previous close of $457.89.
Share price, past year
1Y +34.35%Monthly closing prices
| Date | Close |
|---|---|
| Oct 9, 2026 | $452.63 |
| Sep 30, 2026 | $458.00 |
| Aug 31, 2026 | $456.97 |
| Jul 31, 2026 | $449.76 |
| Jun 30, 2026 | $458.29 |
| May 29, 2026 | $439.48 |
| Apr 30, 2026 | $439.92 |
| Mar 31, 2026 | $407.54 |
| Feb 27, 2026 | $417.24 |
| Jan 30, 2026 | $410.12 |
| Dec 31, 2025 | $376.19 |
| Nov 28, 2025 | $349.74 |
| Oct 31, 2025 | $350.95 |
Key statistics
- Market cap
- $4.78B
- P/E (TTM)
- —
- EPS (TTM)
- −$3.11
- Revenue (TTM)
- $102.94M
- Net income (TTM)
- −$27.76M
- Shares outstanding
- 10.5M
- Dividend yield
- —
- 52-week range
- $335.35 – $469.23
Biodesix's market cap is $4.78B, based on a share price of $452.63 and 10.5M shares outstanding as of Jun 30, 2026.
Financials
Biodesix reported revenue of $88.50M for fiscal 2025, up 24.08% from fiscal 2024.
Biodesix reported a net loss of $35.27M in fiscal 2025.
Fiscal 2025 revenue was the highest in the 7 years shown.
Annual revenue
| Fiscal year | Revenue | Growth | Net income | Net margin | EPS (diluted) | Free cash flow |
|---|---|---|---|---|---|---|
| FY2025ended Dec 31, 2025 | $88.50M | +24.1% | −$35.27M | −39.9% | −$4.67 | −$23.53M |
| FY2024ended Dec 31, 2024 | $71.32M | +45.3% | −$42.93M | −60.2% | −$6.64 | −$51.88M |
| FY2023ended Dec 31, 2023 | $49.09M | +28.5% | −$52.15M | −106.2% | −$12.80 | −$45.79M |
| FY2022ended Dec 31, 2022 | $38.21M | −29.9% | −$65.45M | −171.3% | −$31.00 | −$48.27M |
| FY2021ended Dec 31, 2021 | $54.51M | +19.6% | −$43.16M | −79.2% | −$31.60 | −$30.46M |
| FY2020ended Dec 31, 2020 | $45.56M | +85.6% | −$65.45M | −143.7% | −$129.60 | −$23.31M |
| FY2019ended Dec 31, 2019 | $24.55M | — | −$30.73M | −125.2% | −$2,539.40 | −$23.04M |
| Quarter | Revenue | Net income | EPS (diluted) |
|---|---|---|---|
| Q2 FY2026ended Jun 30, 2026 | $26.86M | −$7.27M | −$0.71 |
| Q1 FY2026ended Mar 31, 2026 | $25.56M | −$7.79M | −$0.81 |
| Q4 FY2025ended Dec 31, 2025 | $28.76M | −$3.98M | −$0.43 |
| Q3 FY2025ended Sep 30, 2025 | $21.77M | −$8.72M | −$1.16 |
| Q2 FY2025ended Jun 30, 2025 | $20.02M | −$11.47M | −$1.56 |
| Q1 FY2025ended Mar 31, 2025 | $17.96M | −$11.10M | −$1.52 |
| Q4 FY2024ended Dec 31, 2024 | $20.43M | −$8.25M | −$0.84 |
| Q3 FY2024ended Sep 30, 2024 | $18.15M | −$10.26M | −$1.40 |
Company profile
- Name
- Biodesix, Inc.
- Ticker
- BDSX
- Exchange
- NASDAQ
- Industry (SEC SIC)
- Services-Medical Laboratories
- Headquarters
- 919 West Dillon Road, Louisville, CO 80027
- Incorporated in
- DE
- Fiscal year ends
- December
- SEC CIK
- 0001439725
Recent SEC filings
- Aug 5, 2026
- Aug 5, 2026
- May 20, 2026
- May 4, 2026
- May 4, 2026
- Feb 26, 2026
- Feb 26, 2026
- Nov 3, 2025
Frequently asked questions
What is Biodesix's stock price?
Biodesix (BDSX) closed at $452.63 on Oct 9, 2026, down 1.15% from the previous close of $457.89.
What is Biodesix's market cap?
Biodesix's market cap is $4.78B, based on a share price of $452.63 and 10.5M shares outstanding as of Jun 30, 2026.
How much revenue does Biodesix make?
Biodesix reported revenue of $88.50M for fiscal 2025, up 24.08% from fiscal 2024.
Does Biodesix pay a dividend?
Biodesix's recent filings report no dividends declared over the last four quarters.
Sources and methodology
Fundamentals come from Biodesix, Inc.'s filings with the SEC (EDGAR XBRL company facts). Fourth-quarter figures that companies don't report separately are calculated as the fiscal year minus the first three quarters. Trailing twelve-month (TTM) figures sum the latest four quarters. Prices are generated sample data for development. Last updated Oct 9, 2026. Data sources and disclosures